Wearable Defibrillator Protects Children at Risk
By HospiMedica International staff writers Posted on 28 Dec 2015 |
A novel wearable defibrillator now offers an advanced protection and monitoring option for children at risk of sudden cardiac arrest.
The LifeVest is a wearable defibrillator, which unlike an implantable cardioverter defibrillator (ICD) is worn on the body (under clothing), rather than implanted into it. Weighing less than one kilogram, the device consists of two main components: an electrode belt and vest-like garment that surround the patient’s chest, and a monitor that the patient wears around the waist. The pediatric device is intended only for children weighing at least 18 kg and with a chest size of 66 cm or more, which is about the size of an average eight year old.
The device continuously monitors the patient's heart using dry, non-adhesive sensing electrodes that detect abnormal heart rhythms. If such a life-threatening cardiac rhythm is detected, the device alerts the patient prior to delivering a shock, thus allowing a conscious patient to postpone the treatment shock. If, on the other hand, the patient is unconscious, the device releases a special gel over the therapy electrodes and delivers an electrical shock to restore normal rhythm.
The LifeVest Wearable Cardioverter Defibrillator is a product of Zoll Medical Corporation (Zoll; Chelmsford, MA, USA), and has been approved by the US Food and Drug Administration (FDA) for children who are at risk for sudden cardiac arrest, but are not candidates for an ICD due to certain medical conditions or lack of parental consent. The device was previously approved in 2001 for patients 18 years of age and older.
“The pediatric medical community is often forced to use adult devices off-label without appropriate labeling or instructions for use in pediatric patients,” said Vasum Peiris, MD, MPH, chief medical officer of pediatrics and special populations in the FDA Center for Devices and Radiological Health (CDRH). “Doctors now have important information that may help them safely prescribe this life-saving device to young patients who may benefit from the device.”
Ventricular fibrillation (VF) and ventricular tachycardia (VT) are life-threatening abnormal heart rhythms that are the most common cause of sudden cardiac arrest (SCA), according to the US National Heart, Lung and Blood Institute (Bethesda, MD, USA). Certain diseases and conditions that can lead to SCA include heart disease, inherited disorders, and structural changes in the heart due to infection or congenital heart disease. Most people who have SCA die from it, often within minutes. Rapid treatment with a defibrillator can save lives.
Related Links:
Zoll Medical Corporation
US National Heart, Lung and Blood Institute
The LifeVest is a wearable defibrillator, which unlike an implantable cardioverter defibrillator (ICD) is worn on the body (under clothing), rather than implanted into it. Weighing less than one kilogram, the device consists of two main components: an electrode belt and vest-like garment that surround the patient’s chest, and a monitor that the patient wears around the waist. The pediatric device is intended only for children weighing at least 18 kg and with a chest size of 66 cm or more, which is about the size of an average eight year old.
The device continuously monitors the patient's heart using dry, non-adhesive sensing electrodes that detect abnormal heart rhythms. If such a life-threatening cardiac rhythm is detected, the device alerts the patient prior to delivering a shock, thus allowing a conscious patient to postpone the treatment shock. If, on the other hand, the patient is unconscious, the device releases a special gel over the therapy electrodes and delivers an electrical shock to restore normal rhythm.
The LifeVest Wearable Cardioverter Defibrillator is a product of Zoll Medical Corporation (Zoll; Chelmsford, MA, USA), and has been approved by the US Food and Drug Administration (FDA) for children who are at risk for sudden cardiac arrest, but are not candidates for an ICD due to certain medical conditions or lack of parental consent. The device was previously approved in 2001 for patients 18 years of age and older.
“The pediatric medical community is often forced to use adult devices off-label without appropriate labeling or instructions for use in pediatric patients,” said Vasum Peiris, MD, MPH, chief medical officer of pediatrics and special populations in the FDA Center for Devices and Radiological Health (CDRH). “Doctors now have important information that may help them safely prescribe this life-saving device to young patients who may benefit from the device.”
Ventricular fibrillation (VF) and ventricular tachycardia (VT) are life-threatening abnormal heart rhythms that are the most common cause of sudden cardiac arrest (SCA), according to the US National Heart, Lung and Blood Institute (Bethesda, MD, USA). Certain diseases and conditions that can lead to SCA include heart disease, inherited disorders, and structural changes in the heart due to infection or congenital heart disease. Most people who have SCA die from it, often within minutes. Rapid treatment with a defibrillator can save lives.
Related Links:
Zoll Medical Corporation
US National Heart, Lung and Blood Institute
Read the full article by registering today, it's FREE!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
- Free digital version edition of HospiMedica International sent by email on regular basis
- Free print version of HospiMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of HospiMedica International in digital format
- Free HospiMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergency Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure